Aldeyra Therapeutics, Inc.
$1.78
▼
-1.19%
2026-04-21 05:12:01
www.aldeyra.com
NCM: ALDX
Explore Aldeyra Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$105.92 M
Current Price
$1.78
52W High / Low
$6.17 / $1.07
Stock P/E
—
Book Value
$0.74
Dividend Yield
—
ROCE
-79.69%
ROE
-58.73%
Face Value
—
EPS
$-0.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
1.33
Debt / Equity
35.1
Current Ratio
2.58
Quick Ratio
2.58
Forward P/E
-6.91
Price / Sales
—
Enterprise Value
$52.61 M
EV / EBITDA
-1.5
EV / Revenue
—
Rating
Buy
Target Price
$7.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
| 2. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 3. | Voyager Therapeutics, Inc. | $4.23 | — | $252.11 M | — | -58.41% | -48.29% | $5.55 / $2.65 | $3.32 |
| 4. | Compugen Ltd. | $2.88 | 7.61 | $269 M | — | 23.38% | 44.84% | $2.94 / $1.23 | $1.09 |
| 5. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 6. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 7. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.67 M | -8 M | -10.17 M | -10.43 M | -16.58 M | — |
| Net Profit | -6.46 M | -7.69 M | -9.77 M | -9.93 M | -15.81 M | — |
| EPS in Rs | -0.11 | -0.13 | -0.16 | -0.16 | -0.26 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -35.27 M | -60.12 M | -42.79 M | -62.68 M |
| Net Profit | -33.85 M | -55.85 M | -37.54 M | -62.02 M |
| EPS in Rs | -0.56 | -0.93 | -0.62 | -1.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 72.06 M | 104.61 M | 148.33 M | 181.29 M |
| Total Liabilities | 27.81 M | 33.6 M | 28.53 M | 30.28 M |
| Equity | 44.25 M | 71 M | 119.8 M | 151.01 M |
| Current Assets | 71.78 M | 104.07 M | 147.81 M | 181.02 M |
| Current Liabilities | 27.81 M | 18.6 M | 22.26 M | 15.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -33.35 M | -43.21 M | -30.33 M | -56.64 M |
| Investing CF | 47.74 M | -44.92 M | 30 M | -29.95 M |
| Financing CF | 1.12 M | -0.17 M | -1.27 M | 1.22 M |
| Free CF | -33.35 M | -43.21 M | -30.33 M | -56.65 M |
| Capex | — | — | — | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -48.77% | 39.47% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.